A headline price is the start, not the total. Four things commonly move it: a required membership, shipping, dose-based increases, and prepayment that locks you in. Here’s how the tracked providers stack up across all four.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Membership | Shipping | Dose increase | Prepay lock-in | Provenance |
|---|---|---|---|---|---|
| NexLife | None | Free | None (flat) | Only for lowest rate | primary |
| Henry Meds | None (stated) | Included | None (flat) | Not confirmed | secondary |
| Fifty 410 | None | Free refrigerated | Yes (tiered) | Multi-month prepaid | primary |
| Mochi Health | ~$79/mo | Not confirmed | Verify per dose | Verify | secondary |
No single provider is “cleanest” on every axis: Fifty 410 has the lowest entry but dose increases and prepay; flat-rate providers avoid dose increases but cost more to start; Mochi’s membership is the clearest add-on. Total it at your dose — total monthly cost.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.